• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

WHI-P154增强了抗癌药物在ABCG2过表达细胞中的化疗效果。

WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.

作者信息

Zhang Hui, Zhang Yun-Kai, Wang Yi-Jun, Kathawala Rishil J, Patel Atish, Zhu Hua, Sodani Kamlesh, Talele Tanaji T, Ambudkar Suresh V, Chen Zhe-Sheng, Fu Li-Wu

机构信息

Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St John's University, Queens, New York, USA.

出版信息

Cancer Sci. 2014 Aug;105(8):1071-8. doi: 10.1111/cas.12462. Epub 2014 Aug 21.

DOI:10.1111/cas.12462
PMID:24903205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4317847/
Abstract

ATP-binding cassette (ABC) transmembrane proteins evidently decrease the intracellular accumulation of substrate chemotherapeutic drugs by extruding them against a concentration gradient, thereby inducing drug resistance. Here we reported the effect of WHI-P154, an irreversible inhibitor of Janus kinase 3 and epidermal growth factor receptor tyrosine kinases, on reversing ABC transporters-mediated drug resistance. We found that WHI-P154 significantly enhanced the sensitivity of ABCG2-overexpressing cells to its substrates. WHI-P154 moderately sensitized ABCB1-overexpressing KB-C2 cells to its substrates whereas showed no sensitizing effect on ABCC1-, ABCC2 or ABCC10-mediated drug resistance. Moreover, WHI-P154 produced a significant increase in the intracellular accumulation of [³H]-mitoxantrone in ABCG2-overexpressing cells. The expression levels nor the localization of the ABCG2 protein was altered after treatment of ABCG2-overexpressing cells with WHI-P154. Further studies indicated that WHI-P154 enhanced the ATPase activity of ABCG2 at low concentrations (<10 μM). Additionally, a docking model predicted the binding conformation of WHI-P154 within the transmembrane region of homology-modeled human ABCG2 transporter. Collectively, these findings highlighted WHI-P154 could significantly reverse ABCG2-mediated multidrug drug resistance by directly blocking the efflux function.

摘要

ATP结合盒(ABC)跨膜蛋白显然通过逆浓度梯度将底物化疗药物排出细胞,从而降低其在细胞内的蓄积,进而诱导耐药性。在此,我们报告了Janus激酶3和表皮生长因子受体酪氨酸激酶的不可逆抑制剂WHI-P154对逆转ABC转运蛋白介导的耐药性的作用。我们发现,WHI-P154显著增强了过表达ABCG2的细胞对其底物的敏感性。WHI-P154使过表达ABCB1的KB-C2细胞对其底物产生适度的敏感性,而对ABCC1、ABCC2或ABCC10介导的耐药性没有增敏作用。此外,WHI-P154使过表达ABCG2的细胞内[³H] - 米托蒽醌的蓄积显著增加。用WHI-P154处理过表达ABCG2的细胞后,ABCG2蛋白的表达水平和定位均未改变。进一步研究表明,低浓度(<10 μM)时,WHI-P154增强了ABCG2的ATP酶活性。此外,一个对接模型预测了WHI-P154在同源建模的人ABCG2转运蛋白跨膜区域内的结合构象。总的来说,这些发现突出表明WHI-P154可通过直接阻断外排功能显著逆转ABCG2介导的多药耐药性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/1953f23730b4/cas0105-1071-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/c7c056693a09/cas0105-1071-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/84a6f959d87a/cas0105-1071-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/592741e775ae/cas0105-1071-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/3653d72ad4be/cas0105-1071-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/1953f23730b4/cas0105-1071-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/c7c056693a09/cas0105-1071-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/84a6f959d87a/cas0105-1071-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/592741e775ae/cas0105-1071-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/3653d72ad4be/cas0105-1071-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82e3/4317847/1953f23730b4/cas0105-1071-f5.jpg

相似文献

1
WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.WHI-P154增强了抗癌药物在ABCG2过表达细胞中的化疗效果。
Cancer Sci. 2014 Aug;105(8):1071-8. doi: 10.1111/cas.12462. Epub 2014 Aug 21.
2
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.林西替尼(OSI-906)可拮抗ATP结合盒转运体G成员2和C成员10介导的耐药性。
Int J Biochem Cell Biol. 2014 Jun;51:111-9. doi: 10.1016/j.biocel.2014.03.026. Epub 2014 Apr 12.
3
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.拉帕替尼(泰立沙,GW572016)通过抑制ATP结合盒亚家族B成员1和G成员2的活性来逆转癌细胞中的多药耐药性。
Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499.
4
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.厄洛替尼(特罗凯,OSI-774)可拮抗ATP结合盒转运体B成员1和ATP结合盒转运体G成员2介导的耐药性。
Cancer Res. 2007 Nov 15;67(22):11012-20. doi: 10.1158/0008-5472.CAN-07-2686.
5
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.表皮生长因子酪氨酸激酶抑制剂AG1478和厄洛替尼可逆转ABCG2介导的耐药性。
Oncol Rep. 2009 Feb;21(2):483-9.
6
Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.沃鲁西利布,一种强效的细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂,可拮抗ABCB1和ABCG2介导的癌细胞多药耐药性。
Cell Physiol Biochem. 2018;45(4):1515-1528. doi: 10.1159/000487578. Epub 2018 Feb 19.
7
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.达可替尼通过抑制 ABCB1 和 ABCG2 转运蛋白的外排活性来拮抗癌细胞中的多药耐药(MDR)。
Cancer Lett. 2018 May 1;421:186-198. doi: 10.1016/j.canlet.2018.01.021. Epub 2018 Jan 11.
8
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.人 ABCB1(P-糖蛋白)和 ABCG2 介导对 BI 2536 的耐药性,BI 2536 是一种有效的 Polo 样激酶 1 选择性抑制剂。
Biochem Pharmacol. 2013 Oct 1;86(7):904-13. doi: 10.1016/j.bcp.2013.08.004. Epub 2013 Aug 17.
9
AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.AST1306,一种有效的 EGFR 抑制剂,拮抗 ABCG2 介导的多药耐药。
Cancer Lett. 2014 Aug 1;350(1-2):61-8. doi: 10.1016/j.canlet.2014.04.008. Epub 2014 Apr 18.
10
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.根据阿克 1 抑制剂塞尔索替尼(GS-4997),可拮抗 ABCB1 和 ABCG2 过表达的癌细胞中的多药耐药性。
Cancer Lett. 2019 Jan;440-441:82-93. doi: 10.1016/j.canlet.2018.10.007. Epub 2018 Oct 10.

引用本文的文献

1
Contribution and expression of renal drug transporters in renal cell carcinoma.肾药物转运体在肾细胞癌中的作用及表达
Front Pharmacol. 2025 Feb 17;15:1466877. doi: 10.3389/fphar.2024.1466877. eCollection 2024.
2
Drug resistance of hepatoma cells induced by ATP‑binding cassette transporter G2 by reducing intracellular drug concentration.ATP结合盒转运蛋白G2通过降低细胞内药物浓度诱导肝癌细胞耐药。
Exp Ther Med. 2023 Feb 6;25(3):124. doi: 10.3892/etm.2023.11823. eCollection 2023 Mar.
3
Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.

本文引用的文献

1
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.林西替尼(OSI-906)可拮抗ATP结合盒转运体G成员2和C成员10介导的耐药性。
Int J Biochem Cell Biol. 2014 Jun;51:111-9. doi: 10.1016/j.biocel.2014.03.026. Epub 2014 Apr 12.
2
Genetic Interactions of STAT3 and Anticancer Drug Development.STAT3 的遗传相互作用与抗癌药物开发。
Cancers (Basel). 2014 Mar 6;6(1):494-525. doi: 10.3390/cancers6010494.
3
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10).
新型茚并[1,2-b]吲哚抑制乳腺癌耐药蛋白的作用机制。
Sci Rep. 2021 Jan 19;11(1):1788. doi: 10.1038/s41598-020-79892-w.
4
Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo.用于细胞毒性蛋白细胞内递送以克服ABC转运蛋白介导的多药耐药性的脂质-皂草素纳米颗粒:体外和体内研究
Cancers (Basel). 2020 Feb 21;12(2):498. doi: 10.3390/cancers12020498.
5
The epigallocatechin gallate derivative Y reverses drug resistance mediated by the ABCB1 transporter both and .表没食子儿茶素没食子酸酯衍生物Y在体内和体外均能逆转由ABCB1转运蛋白介导的耐药性。
Acta Pharm Sin B. 2019 Mar;9(2):316-323. doi: 10.1016/j.apsb.2018.10.001. Epub 2018 Oct 12.
6
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.调节 2 型乳头状肾细胞癌中的 ATP 结合盒转运蛋白可增强其对靶向分子治疗的反应。
Mol Oncol. 2018 Oct;12(10):1673-1688. doi: 10.1002/1878-0261.12346. Epub 2018 Aug 23.
7
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.酪氨酸激酶抑制剂增强了多药耐药癌细胞中常规化疗药物的疗效。
Mol Cancer. 2018 Feb 19;17(1):25. doi: 10.1186/s12943-018-0775-3.
8
Cytokine Signaling in Tumor Progression.肿瘤进展中的细胞因子信号传导
Immune Netw. 2017 Aug;17(4):214-227. doi: 10.4110/in.2017.17.4.214. Epub 2017 Aug 9.
9
GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance.强效胰岛素样生长因子-1受体(IGF-IR)抑制剂GSK1904529A可逆转多药耐药相关蛋白1(MRP1)介导的多药耐药。
J Cell Biochem. 2017 Oct;118(10):3260-3267. doi: 10.1002/jcb.25975. Epub 2017 May 3.
10
Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.巴非替尼(INNO-406)通过抑制ABCB1和ABCG2转运蛋白的外排功能来逆转多药耐药性。
Sci Rep. 2016 May 9;6:25694. doi: 10.1038/srep25694.
坦度替尼(MLN518)通过抑制多药耐药蛋白 7(ABCC10)的外排活性来逆转多药耐药。
Oncol Rep. 2013 Jun;29(6):2479-85. doi: 10.3892/or.2013.2362. Epub 2013 Mar 22.
4
Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.尼洛替尼增强了 ABCB1、ABCG2 和 ABCC10 多药耐药异种移植模型中小鼠的抗癌药物敏感性。
Cancer Lett. 2013 Jan 28;328(2):307-17. doi: 10.1016/j.canlet.2012.10.001. Epub 2012 Oct 9.
5
Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.扎鲁司特拮抗三磷酸腺苷结合盒 subfamily G 成员 2 介导的多药耐药。
Anticancer Drugs. 2012 Sep;23(8):865-73. doi: 10.1097/CAD.0b013e328354a196.
6
Janus kinase 3: the controller and the controlled.Janus 激酶 3:调控者与被调控者。
Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):187-96. doi: 10.1093/abbs/gmr105. Epub 2011 Nov 29.
7
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.多药耐药蛋白(MRPs/ABCCs)在癌症化疗和遗传疾病中的作用。
FEBS J. 2011 Sep;278(18):3226-45. doi: 10.1111/j.1742-4658.2011.08235.x. Epub 2011 Aug 1.
8
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.西地那非逆转 ABCB1 和 ABCG2 介导的化疗药物耐药性。
Cancer Res. 2011 Apr 15;71(8):3029-41. doi: 10.1158/0008-5472.CAN-10-3820. Epub 2011 Mar 14.
9
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.阿帕替尼(YN968D1)通过抑制多种三磷酸腺苷结合盒转运蛋白的外排功能逆转多药耐药。
Cancer Res. 2010 Oct 15;70(20):7981-91. doi: 10.1158/0008-5472.CAN-10-0111. Epub 2010 Sep 28.
10
Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters.基于药物信息学方法设计 ABC 转运体的天然产物型配体。
Curr Pharm Des. 2010 May;16(15):1742-52. doi: 10.2174/138161210791163992.